Benzinga
Benzinga
Benzinga
mercredi, septembre 30

Nautilus Biotechnology Inc

NAUTNASDAQ
Trade with Public
Trade with Public
$1.36
0.2522.97%
À la clôture: Sep 28, 5:00 PM EST
$1.61
0.5045.05%
Pré-ouverture: 8:55 AM EST
PRO
Pourquoi cela bouge-t-il ?:Nautilus Biotechnology shares are trading higher after Roth Capital initiat...
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Nautilus Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nautilus Biotechnology (NAUT).

Price Target Range — 4 Quarters

Analyst Consensus — 5 Analysts

3Buy
1Hold
1Sell
Consensus RatingBuy# Analysts5Avg. Consensus PT$3Upside to Avg. PT+101.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026Roth CapitalMax MasucciInitiateBuy$4
Sep 9, 2026Leerink PartnersPuneet SoudaInitiateOutperform$4
More with Benzinga EdgeGet Access

Analyst Ratings News

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).
Avi Kapoor

PRO
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

Guggenheim analyst Subbu Nambi maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Buy and raises the price target from $2.5 to $4.
Benzinga Newsdesk

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

Goldman Sachs analyst Matthew Sykes downgrades Nautilus Biotechnology (NASDAQ:NAUT) from Neutral to Sell and lowers the price target from $2.25 to $1.75.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved